<!DOCTYPE html>
<html lang="ko">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>RegScan 브리핑 - POLATUZUMAB VEDOTIN-PIIQ</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Noto+Serif+KR:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap');

        body {
            font-family: 'Noto Serif KR', serif;
            background: #fafafa;
        }

        .report-title {
            font-family: 'Noto Serif KR', serif;
            font-weight: 700;
        }

        .report-body {
            font-family: 'Noto Serif KR', serif;
            line-height: 1.9;
            font-size: 17px;
        }

        .meta-text {
            font-family: 'Inter', sans-serif;
        }

        .highlight-box {
            border-left: 4px solid #dc2626;
            background: linear-gradient(90deg, #fef2f2 0%, #ffffff 100%);
        }

        .timeline-dot {
            width: 12px;
            height: 12px;
            border-radius: 50%;
        }
    </style>
</head>
<body class="min-h-screen">
    <!-- Header -->
    <header class="bg-white border-b border-gray-200 sticky top-0 z-50">
        <div class="max-w-4xl mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-3">
                    <span class="text-xl font-bold text-gray-900">MedClaim</span>
                    <span class="text-gray-300">|</span>
                    <span class="text-sm text-gray-500 meta-text">RegScan 브리핑</span>
                </div>
                <div class="meta-text text-sm text-gray-500">
                    2026년 02월 05일
                </div>
            </div>
        </div>
    </header>

    <!-- Main Content -->
    <main class="max-w-4xl mx-auto px-6 py-10">
        <!-- Category & Tags -->
        <div class="flex items-center space-x-3 mb-6 meta-text">
            <span class="px-3 py-1 bg-red-600 text-white text-xs font-semibold rounded">HOT ISSUE</span>
            <span class="px-3 py-1 bg-gray-100 text-gray-600 text-xs rounded">희귀의약품</span>
        </div>

        <!-- Title -->
        <h1 class="report-title text-4xl text-gray-900 mb-4 leading-tight">
            주요 질환 치료제 POLATUZUMAB VEDOTIN, 글로벌 승인 완료
        </h1>

        <!-- Subtitle -->
        <p class="text-xl text-gray-600 mb-8 leading-relaxed">
            FDA·EMA·MFDS 승인, 국내는 급여 미적용
        </p>

        <!-- Author & Date -->
        <div class="flex items-center space-x-4 mb-10 pb-10 border-b border-gray-200 meta-text">
            <div class="flex items-center space-x-2">
                <div class="w-8 h-8 bg-indigo-100 rounded-full flex items-center justify-center">
                    <span class="text-indigo-600 text-xs font-bold">AI</span>
                </div>
                <span class="text-sm text-gray-600">RegScan AI 리포터</span>
            </div>
            <span class="text-gray-300">·</span>
            <span class="text-sm text-gray-500">Hot Issue Score: 75</span>
        </div>

        <!-- Key Points Box -->
        <div class="highlight-box p-6 rounded-r-lg mb-10">
            <h3 class="font-bold text-gray-900 mb-3 meta-text text-sm">핵심 요약</h3>
            <ul class="space-y-2 text-gray-800">
                <li class="flex items-start">
                    <span class="text-red-500 mr-2">▸</span>
                    <span>FDA 승인 2023년 4월, EMA 승인 2020년 1월</span>
                </li>
                <li class="flex items-start">
                    <span class="text-red-500 mr-2">▸</span>
                    <span>MFDS 승인 완료했으나 HIRA 급여 미적용</span>
                </li>
                <li class="flex items-start">
                    <span class="text-red-500 mr-2">▸</span>
                    <span>희귀의약품으로 분류된 주요 질환 치료제</span>
                </li>
                <li class="flex items-start">
                    <span class="text-red-500 mr-2">▸</span>
                    <span>CRIS에 임상시험 정보 없음</span>
                </li>
            </ul>
        </div>

        <!-- Article Body -->
        <article class="report-body text-gray-800">
            <h2 class="text-2xl font-bold text-gray-900 mt-10 mb-4">글로벌 승인 현황</h2>

            <p class="mb-6">
                POLATUZUMAB VEDOTIN은 2023년 4월 FDA, 2020년 1월 EMA에서 승인받은 항암제입니다. 희귀의약품으로 분류되어 주요 질환 치료에 사용됩니다.
            </p>

            <!-- Timeline Visual -->
            <div class="my-10 p-6 bg-gray-50 rounded-xl">
                <h4 class="meta-text text-sm font-semibold text-gray-500 mb-6">승인 타임라인</h4>
                <div class="relative">
                    <div class="absolute left-2 top-0 bottom-0 w-0.5 bg-gray-300"></div>

                    <div class="relative flex items-center mb-6">
                        <div class="timeline-dot bg-yellow-500 z-10"></div>
                        <div class="ml-6">
                            <div class="meta-text text-xs text-yellow-600 font-semibold">2020-01-16</div>
                            <div class="font-medium ">🇪🇺 EMA 승인</div>
                            <div class="text-sm text-gray-500">Authorised</div>
                        </div>
                    </div>
                    <div class="relative flex items-center mb-6">
                        <div class="timeline-dot bg-green-500 z-10"></div>
                        <div class="ml-6">
                            <div class="meta-text text-xs text-green-600 font-semibold">2020-10-27</div>
                            <div class="font-medium ">🇰🇷 MFDS 허가</div>
                            <div class="text-sm text-gray-500">폴라이비주(폴라투주맙베도틴)</div>
                        </div>
                    </div>
                    <div class="relative flex items-center mb-6">
                        <div class="timeline-dot bg-blue-500 z-10"></div>
                        <div class="ml-6">
                            <div class="meta-text text-xs text-blue-600 font-semibold">2023-04-19</div>
                            <div class="font-medium ">🇺🇸 FDA 승인</div>
                            <div class="text-sm text-gray-500">Approved</div>
                        </div>
                    </div>
                </div>
            </div>

            <h2 class="text-2xl font-bold text-gray-900 mt-10 mb-4">국내 도입 전망</h2>

            <p class="mb-6">
                국내에서는 MFDS에서 2020년 10월에 허가를 받았지만, HIRA에서 급여 상태는 미등재로 확인되었습니다. 현재 CRIS에 임상시험 등록은 없습니다.
            </p>

            <!-- MedClaim Box -->
            <div class="my-10 p-6 bg-indigo-50 rounded-xl border border-indigo-100">
                <h4 class="meta-text text-sm font-semibold text-indigo-600 mb-3">💡 메드클레임 시사점</h4>
                <div class="space-y-3 text-gray-800">
                    <p>POLATUZUMAB VEDOTIN의 급여 미적용으로 비급여 상태입니다. 환자 부담은 약 100%이며, 실손보험 청구는 가능하지만 환자에게는 전액 부담이 예상됩니다.</p>

                </div>
            </div>

            <!-- CRIS Trials -->
            
        </article>

        <!-- Source & Disclaimer -->
        <footer class="mt-16 pt-8 border-t border-gray-200 meta-text text-sm text-gray-500">
            <div class="mb-4">
                <strong>데이터 출처:</strong> FDA Drug Approvals Database, EMA Public Assessment Reports,
                MFDS 의약품통합정보시스템, CRIS 임상연구정보서비스, HIRA 건강보험심사평가원
            </div>
            <div class="text-xs text-gray-400">
                본 리포트는 RegScan AI가 공개 데이터를 기반으로 자동 생성한 브리핑 자료입니다.
                의사결정에 활용 시 원문 확인을 권장합니다.
                마지막 업데이트: 2026-02-05
            </div>
        </footer>
    </main>
</body>
</html>
